Opus Genetics Correlations

IRD Stock   1.93  0.07  3.50%   
The current 90-days correlation between Opus Genetics and Acumen Pharmaceuticals is 0.2 (i.e., Modest diversification). The correlation of Opus Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Opus Genetics Correlation With Market

Average diversification

The correlation between Opus Genetics and DJI is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Opus Genetics and DJI in the same portfolio, assuming nothing else is changed.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.

Moving against Opus Stock

  0.45SNY Sanofi ADRPairCorr
  0.31HCM HUTCHMED DRCPairCorr
  0.42T ATT IncPairCorr

Related Correlations Analysis


Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

TILSEER
HURASEER
VTGNAGEN
TILHURA
HURAVTGN
TILINO
  

High negative correlations

AGENABOS
MCRBABOS
VTGNABOS

Risk-Adjusted Indicators

There is a big difference between Opus Stock performing well and Opus Genetics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Opus Genetics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ABOS  4.35 (0.07) 0.00  0.05  4.67 
 10.29 
 30.69 
SEER  1.46 (0.24) 0.00 (0.29) 0.00 
 3.28 
 9.98 
AGEN  2.75 (0.23) 0.00 (0.04) 0.00 
 5.78 
 21.03 
INO  4.00 (0.56) 0.00 (0.84) 0.00 
 7.11 
 36.52 
VTGN  5.68 (1.41) 0.00 (1.08) 0.00 
 7.93 
 96.59 
HURA  4.42 (1.76) 0.00 (0.56) 0.00 
 7.73 
 50.34 
ALEC  4.06 (0.63) 0.00 (0.13) 0.00 
 6.14 
 58.73 
CGTX  4.11 (0.37) 0.00 (0.10) 0.00 
 10.07 
 24.96 
TIL  4.86 (1.22) 0.00 (0.77) 0.00 
 8.09 
 56.30 
MCRB  4.20 (0.08) 0.00  0.18  0.00 
 9.13 
 54.10 

Opus Genetics Corporate Management

Joseph MBAChief OfficerProfile
Jenny KobinInvestor OfficerProfile
Robert GagnonChief OfficerProfile
Bernhard MBASenior SecretaryProfile
Ashwath JayagopalChief OfficerProfile
Bindu ManneHead CommercializationProfile